Literature DB >> 8901080

Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.

C Madhu1, P J Rix, M J Shackleton, T G Nguyen, D D Tang-Liu.   

Abstract

This study was designed to examine the effect of benzalkonium chloride/ethylenediaminetetraacetic acid (BAK/EDTA) on the ocular bioavailability (Focular) of ketorolac tromethamine after ocular instillation to normal and de-epithelialized corneas of rabbits both in vitro and in vivo. The in vitro Focular of the formulations was measured in flow-through perfusion chambers. For in vivo studies, a 35 microL dose of 0.5% ketorolac tromethamine with or without BAK/EDTA was instilled into rabbit eyes with intact or de-epithelialized corneas. At 0.5, 1, 2, 4, 6, and 8 h postdose, rabbits were euthanized, and the corneas and aqueous humor were collected from both eyes. The ketorolac concentrations from both in vivo and in vitro samples were quantified by reversed-phase high-performance liquid chromatography. The in vitro study results indicated that BAK/EDTA statistically significantly increased the Focular of ketorolac through de-epithelialized corneas but not through intact corneas. The in vivo study results showed that BAK/EDTA had no effect on the Focular of ketorolac in rabbits with intact corneas, based on the values of the area under the aqueous humor concentration versus time curves (AUC0-6h) of ketorolac. As expected, de-epithelialization of the corneas produced a faster and greater ocular absorption of ketorolac as evidenced by the smaller Tmax and larger AUC values compared to those for the intact corneas in vivo. However, BAK/EDTA decreased the ocular absorption of ketorolac in rabbits with de-epithelialized corneas. The half-lives (t 1/2) of ketorolac in corneal tissue and aqueous humor were longer in rabbits with intact corneas than those in rabbits with de-epithelialized corneas. In conclusion, the in vivo Focular of ketorolac was not altered by BAK/EDTA in rabbits with intact corneas, but it was decreased by BAK/EDTA in rabbits with de-epithelialized corneas. Therefore, the formulation with ketorolac alone may be better as a post-operative ocular analgesic.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901080     DOI: 10.1021/js9504189

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2005-10-24       Impact factor: 3.246

2.  NC-1059: a channel-forming peptide that modulates drug delivery across in vitro corneal epithelium.

Authors:  Jesica Martin; Pradeep Malreddy; Takeo Iwamoto; Lisa C Freeman; Harriet J Davidson; John M Tomich; Bruce D Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

3.  Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas.

Authors:  Pravin Kondiba Pawar; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006-02-10       Impact factor: 3.246

4.  Ocular pharmacokinetics of 0.45% ketorolac tromethamine.

Authors:  Mayssa Attar; Rhett Schiffman; Lisa Borbridge; Quinn Farnes; Devin Welty
Journal:  Clin Ophthalmol       Date:  2010-12-01

5.  Effect of in vitro transcorneal approach of aceclofenac eye drops through excised goat, sheep, and buffalo corneas.

Authors:  Vivek Dave; Sarvesh Paliwal; Sachdev Yadav; Swapnil Sharma
Journal:  ScientificWorldJournal       Date:  2015-01-13

6.  Effects of topical flurbiprofen sodium, diclofenac sodium, ketorolac tromethamine and benzalkonium chloride on corneal sensitivity in normal dogs.

Authors:  Raquel de Araújo Cantarella; Juliana Kravetz de Oliveira; Daniel M Dorbandt; Fabiano Montiani-Ferreira
Journal:  Open Vet J       Date:  2017-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.